INmune Bio (INmune Bio) Debt-to-Equity : 0.27 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Debt-to-Equity?

INmune Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $7.58 Mil. INmune Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.36 Mil. INmune Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $29.02 Mil. INmune Bio's debt to equity for the quarter that ended in Mar. 2024 was 0.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for INmune Bio's Debt-to-Equity or its related term are showing as below:

INMB' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.35 Med: 0.19 Max: 0.34
Current: 0.27

During the past 8 years, the highest Debt-to-Equity Ratio of INmune Bio was 0.34. The lowest was -2.35. And the median was 0.19.

INMB's Debt-to-Equity is ranked worse than
62.29% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs INMB: 0.27

INmune Bio Debt-to-Equity Historical Data

The historical data trend for INmune Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Debt-to-Equity Chart

INmune Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.19

0.26

0.27

INmune Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.28	0.30	0.29	0.27	0.27

Competitive Comparison of INmune Bio's Debt-to-Equity

For the Biotechnology subindustry, INmune Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where INmune Bio's Debt-to-Equity falls into.

INmune Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

INmune Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.04	+	0.397)	/	38.139
	=	0.27

INmune Bio's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.58	+	0.36)	/	29.023
	=	0.27

INmune Bio (NAS:INMB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

INmune Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of INmune Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

INmune Bio (INmune Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Executives

Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016